Author/Authors :
Pincus، نويسنده , , Steven E. and Lukacher، نويسنده , , Nadya and Mohamed، نويسنده , , Nehal and Sesay، نويسنده , , Muctarr and Zabinski، نويسنده , , Roger and Ebelle، نويسنده , , Rose and Duncan، نويسنده , , Lisa and Li، نويسنده , , Juan and Chen، نويسنده , , Xun and Peng، نويسنده , , Wu and Adaelu، نويسنده , , Josaih and Casey، نويسنده , , Leslie and Porter، نويسنده , , James P. and Spitalny، نويسنده , , George and Na، نويسنده ,
Abstract :
Autoantibodies that react with double-stranded DNA (dsDNA) are a hallmark for diagnosis of systemic lupus erythematosus (SLE) and are also considered the pathogenic subset that is most associated with lupus nephritis. As an agent to remove the pathogenic dsDNA antibodies from the circulation of SLE patients, we are developing an antigen-based heteropolymer (AHP). The AHP consists of a monoclonal antibody to the complement receptor (CR1) cross-linked to salmon testis dsDNA to effect clearance of anti-DNA antibodies by binding them to erythrocyte CR1. Utilizing a cynomolgus monkey model for SLE in which we infused plasma from SLE patients containing a high titer of high-avidity anti-dsDNA antibody, we have evaluated the safety and efficacy of AHP infusion. The results demonstrate that AHP rapidly (within 2 min of infusion) binds to monkey erythrocytes without causing any toxicological effects. We also demonstrate that human Ig (G+M) antibodies are rapidly bound to the AHP–erythrocyte complex. These events are mirrored in their kinetics by a substantial drop in the level of high-avidity dsDNA antibody in the plasma.
